Raymond James Downgrades Dipexium Pharmaceuticals (DPRX) to Market Perform
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- AMC Entertainment (AMC) Enters $250M ATM Agreement
Dipexium Pharma (DPRX) will resume trading at 7:30am ET
October 25, 2016 7:11 AM EDTDipexium Pharma (Nasdaq: DPRX) will resume trading at 7:30am EDT.
... MoreDipexium Pharma (DPRX) Announces Locilex Phase 3s Missed Primary Endpoints
October 25, 2016 7:04 AM EDTDipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.8%) in patients with mild infections of diabetic foot ulcers (Mild DFI) did not meet the primary clinical endpoint of superiority versus vehicle plus standardized wound care and also did not show any meaningful difference in wound closure rate between the Locilex arm and the vehicle arm in each study. Neither trial met the secondary endpoint of demonstrating a higher rate of eradication of bacteria for the Locilex arm. While the overall adverse event incidence was comparable... More
Dipexium Pharma (DPRX) trading halted with news pending
October 25, 2016 6:56 AM EDTDipexium Pharma (NASDAQ: DPRX) trading halted with news pending.
... More